Supplementary Figure 1: Trajectories of anti-SARS-CoV-2 Spike protein (anti-S) IgG titres in individual patients following first and second doses of vaccine, stratified by disease subtype.
lower limit of assay, **upper limit of assay, HR-MDS High Risk MDS S1A: Line graph seroconversion rates in patients with no previous SARS-CoV-2 inecter
S1D: Seroconversion rates in all patients with previous SARS-CoV-2 infection, after one and two doses of vaccine (Paired pre dose, post first dose and second dose),

$$
\begin{aligned}
& \text { S1D: Seroconversion rates in all patients with previous SARS-CoV-2 infection, } \\
& \text { displayed as a line graph (S1E) }
\end{aligned}
$$

S1D: Seroconversion rates in all patients with previous SARS-CoV-2 infection, after one and two doses of vaccine (Paired pre dose, post first dose and second dose)
displayed as a line graph (S1E)

(Paired pre dose, post first dose and
Supplementary Figure 2: Serological responses in patients with Acute leukaemia stratified by therapy

Figure legend: All figures are presented with a Log10 scale on the $\mathbf{y}$-axis.
Figure legend: All figures are presented with a Log10 scale on the y-axis.
*/ower limit of assay, **upper limit of assay, HR-MDS High Risk MDS
S2A: Serological response following two doses of vaccine in AML/HR-MDS treated with venetoclax-based regimens and no evidence of
previous SARS-COV-2 infection
S2B: Serological response following two doses of vaccine in patients treated with Rituximab and non-Rituximab containing regimes:
Median $342 \mathrm{U} / \mathrm{mL}$ (IQR 1.69-1541) vs Median $7.5 \mathrm{U} / \mathrm{mL}$ (IQR 2.6-751.5) $\mathrm{p}=0.83$
S2C: Serological response following two doses of vaccine in patients treated with Rituximab and non-rituximab containing regimes
(Baseline COVID -ve only): Median 2.980 (IQR 0.4-342) vs Median $6.280 \mathrm{U} / \mathrm{mL}$ (IQR 3.7-239.7) p=0.6

